Method for quantitatively analyzing iodine contrast agent in plasma through ultra-high performance liquid chromatography-tandem mass spectrometry combined device

Through ultra-high performance liquid chromatography-tandem mass spectrometry combined device and internal standard method, the analysis conditions are optimized, and the problems of cumbersome operation and long analysis time of iodine contrast agent in vivo elimination rate detection method are solved, and the rapid and Stable and sensitive quantitative analysis meets the rapid detection needs of clinical research.

CN118937518APending Publication Date: 2024-11-12PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411021761.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing iodine contrast agent elimination rate detection methods in vivo are cumbersome, long analysis time and low sensitivity, which are difficult to meet the needs of fast and accurate detection in clinical research.

Method used

Using ultra-high performance liquid chromatography-tandem mass spectrometry combined device, the plasma sample solution containing iodine contrast agent was prepared and quantitative analysis was performed using the internal standard method. Combined with specific mobile phase composition, elution procedures and mass spectrometry conditions, ionization and Collision parameters to achieve rapid and stable quantitative analysis of iodhellol, iodpromide and iodixanol.

Benefits of technology

The rapid, stable and sensitive quantitative analysis of iodine contrast agent in plasma is achieved, which shortens the analysis time, improves the analysis efficiency, and has good reproducibility and specificity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937518A_ABST
    Figure CN118937518A_ABST
Patent Text Reader

Abstract

The invention provides a method for quantitatively analyzing an iodine contrast agent in plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry device. The method comprises the following steps: 1) preparing a plasma sample solution containing the iodine contrast agent; (2) injecting the plasma sample solution into an ultra-high performance liquid chromatography-tandem mass spectrometry device to obtain a mass chromatogram; and 3) performing quantitative analysis on the iodine contrast agent by using an internal standard method according to the mass chromatogram, the iodine contrast agent comprising at least one selected from iohexol, iopromide and iodixanol, and eluting by using a mixed mobile phase consisting of a mobile phase A and a mobile phase B in the ultra-high performance liquid chromatography, wherein the mobile phase A is acetonitrile and the mobile phase B is an aqueous solution containing 0.1% to 0.5% by volume of formic acid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biochemistry and pharmaceutical analytical chemistry, and in particular, relates to a method for quantitatively analyzing iodine contrast agents in plasma by using an ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) coupling device. Background Art

[0002] Liquid chromatography-mass spectrometry is mainly used in the fields of drug metabolism, pharmacokinetics, clinical pharmacology, and natural drug development. It has the advantages of high sensitivity, high specificity, good reproducibility, accurate quantification, wide linear range, and simple data processing. High performance liquid chromatography can effectively separate the components of the analyte, and mass spectrometry can separate the separated components one by one. Liquid chromatography-mass spectrometry utilizes the different distribution and adsorption coefficients between the mobile phase and the stationary phase of the chromatographic column of each component of the sample. After the mobile phase brings the sample into the chromatographic column for separation, the different ion fragments have different motion behaviors in different electric fields and / or magnetic fields through the interface device. The mass analyzer separates the ions according to the mass-to-charge ratio (m / z) to obtain a mass spectrum arranged in order of mass. By analyzing and processing the mass spectrum, the qualitative and quantitative analysis results of the sample can be obtained.

[0003] Giving patients an additional low dose of iodinated contrast agent during clinical CT angiography and determining its elimination rate in the body is one of the commonly used methods for measuring glomerular filtration rate (GFR). An effective detection method is crucial for measuring the GFR of patients who need angiography, but higher doses of iodinated contrast agents are generally used in clinical angiography. Therefore, clarifying the difference in the elimination of high-dose and low-dose iodinated contrast agents in the body can help reduce the workload of clinical GFR measurement. At present, the commonly used iodinated contrast agents mainly include iodine-containing compounds such as iohexol, iopromide and iodixanol.

[0004] At present, the main analytical methods for determining iodine compounds in biological samples are high-performance liquid chromatography ultraviolet detection (HPLC-UV) and liquid chromatography tandem mass spectrometry (LC-MS / MS). Among them, HPLC-UV has the characteristics of simple operation and low testing cost, but this type of method has low sensitivity and cannot be used for low-dose pharmacokinetic and bioequivalence studies; LC-MS / MS is a chromatographic technology using mass spectrometry as a detection method. It cleverly combines the separation ability of high-performance liquid chromatography with the detection and structural analysis functions of mass spectrometers. It has high sensitivity and high selectivity that other instruments cannot match. It is best when running in multi-stage reaction monitoring (MRM) mode. The drug concentration can reach the picogram (pg) level. It has become one of the most powerful analytical tools for pharmacokinetic and bioequivalence studies at home and abroad.

[0005] At present, there are several papers using LC-MS / MS technology to detect the concentration of iodinated contrast agents such as iohexol, iopromide and iodixanol in plasma. The detection method mainly focuses on iohexol, and the sample pretreatment is cumbersome and the analysis time is long. Therefore, it is urgent to develop a simple, fast and highly accurate detection method to achieve simple sample pretreatment, shortened running time and high-throughput detection to meet the needs of clinical research. Summary of the invention

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides a method for quantitatively analyzing iodinated contrast agents in plasma by ultra-high performance liquid chromatography-tandem mass spectrometry, the method comprising the following steps:

[0007] 1) preparing a plasma sample solution containing an iodinated contrast agent;

[0008] 2) injecting the plasma sample solution into an ultra-high performance liquid chromatography-tandem mass spectrometry device to obtain a mass chromatogram; and

[0009] 3) performing quantitative analysis on the iodine contrast agent using an internal standard method according to the mass chromatogram,

[0010] wherein the iodine contrast agent comprises at least one selected from iohexol, iopromide and iodixanol, and

[0011] The ultra-high performance liquid chromatography uses a mixed mobile phase consisting of mobile phase A and mobile phase B for elution, wherein the mobile phase A is acetonitrile, and the mobile phase B is an aqueous solution containing 0.1% to 0.5% by volume of formic acid. Preferably, the mobile phase B is an aqueous solution containing 0.2% by volume of formic acid.

[0012] In some embodiments, isocratic elution is performed in the ultra-high performance liquid chromatography, and the volume ratio of mobile phase A to mobile phase B in the mixed mobile phase is in the range of 10:90 to 30:70, preferably 20:80.

[0013] In some embodiments, gradient elution is performed in the ultra-high performance liquid chromatography, and the gradient elution program is as follows:

[0014] 0.00 to 1.00 min, 60 vol% to 80 vol% fluidity B;

[0015] 1.00 to 1.50 minutes, 80% to 90% by volume of mobile phase B;

[0016] The total amount of mobile phase A and mobile phase B is 100 volume %.

[0017] In some embodiments, D5-iohexol is used as an internal standard.

[0018] In some embodiments, the chromatographic column in the ultra-high performance liquid chromatography is a reverse phase chromatographic column, preferably a chromatographic column filled with octadecylsilane bonded silica gel. More preferably, the chromatographic column has a size of 2.1×50 mm and a filler particle size of 1.7 μm.

[0019] In some embodiments, the injection volume of the sample solution is 1 to 5 μL, preferably 2 μL.

[0020] In some embodiments, the flow rate of the mixed mobile phase is in the range of 0.3 to 0.5 mL / min, preferably 0.4 mL / min.

[0021] In some embodiments, the column temperature in the HPLC is in the range of 30°C to 50°C, preferably 35°C.

[0022] In some embodiments, the preparation of the plasma sample solution containing the iodinated contrast agent comprises: adding an internal standard working solution to the plasma sample of the subject, shaking the resulting mixture, then centrifuging it, taking the supernatant, adding water thereto, and mixing.

[0023] In some embodiments, the internal standard working solution is prepared by dissolving the internal standard D5-iohexol in water to obtain an internal standard stock solution, and then diluting the internal standard stock solution with methanol.

[0024] In some embodiments, the mass spectrometry conditions include: using a triple tandem quadrupole mass spectrometer in a positive ion mode with an electrospray ionization source and performing multiple reaction monitoring scanning detection.

[0025] In some embodiments, in the tandem mass spectrometry, the capillary voltage is 3.0 kV and the cone voltage is 50V.

[0026] In some embodiments, in the multiple reaction monitoring scanning detection, the quantitative ion pair of iohexol is m / z 821.9→m / z 803.7, the quantitative ion pair of iopromide is m / z 791.9→m / z 572.7, the quantitative ion pair of iodixanol is m / z 1551.2→m / z 1533.0, and the quantitative ion pair of D5-iohexol is m / z 826.5→m / z 808.5.

[0027] In some embodiments, in the tandem mass spectrometer, the collision voltage of iohexol is 30V, the collision voltage of iopromide is 32V, the collision voltage of iodixanol is 35V, and the collision voltage of D5-iohexol is 20V.

[0028] In some embodiments, the mass spectrometry conditions further include: a desolvation gas flow rate of 1000 L / h, an ion source temperature of 500° C., and a collision gas flow rate of 0.10 mL / min.

[0029] In some embodiments, the detection method further comprises preparing one or more of a stock solution of the iodinated contrast agent, a standard curve working solution, a standard curve plasma sample solution, an internal standard stock solution, an internal standard working solution, a quality control working solution, and a quality control plasma sample solution.

[0030] In some embodiments, the preparation method of the stock solution of the iodine contrast agent comprises: weighing a standard of the iodine contrast agent and dissolving it in water. In some embodiments, in the stock solution of the iodine contrast agent, the concentrations of iohexol, iopromide and iodixanol are 25.0 mg / mL, 25.0 mg / mL and 50.0 mg / mL, respectively.

[0031] In some embodiments, the preparation method of the standard curve working solution comprises: taking an appropriate amount of the stock solution of the iodine contrast agent, and further diluting with water to prepare a series of standard curve working solutions of different concentrations. In some embodiments, in the series of standard curve working solutions of different concentrations, the concentration of iohexol is 0.025, 0.125, 0.625, 1.25, 2.50, 6.25, 12.5 and 25.0 mg / mL; the concentration of iopromide is 0.025, 0.125, 0.625, 1.25, 2.50, 6.25, 12.5 and 25.0 mg / mL; the concentration of iodixanol is 0.05, 0.25, 1.25, 2.50, 5.00, 12.5, 25.0 and 50.0 mg / mL.

[0032] In some embodiments, the preparation method of the standard curve plasma sample solution comprises: taking a certain amount of standard curve working solution of different concentrations, diluting with blank plasma, and finally obtaining a series of standard curve plasma sample solutions. In some embodiments, in the standard curve plasma sample solution, the concentration of iohexol is 5.00, 25.0, 125, 250, 500, 1250, 2500 and 5000 μg / mL; the concentration of iopromide is 5.00, 25.0, 125, 250, 500, 1250, 2500 and 5000 μg / mL; the concentration of iodixanol is 10.0, 50.0, 250, 500, 1000, 2500, 5000 and 10000 μg / mL.

[0033] In some embodiments, the method for preparing the quality control working solution comprises: taking an appropriate amount of a stock solution of an iodine contrast agent, and further diluting it with water to prepare a quality control working solution of different concentrations. In some embodiments, in the quality control working solution, the concentration of iohexol is 0.025, 0.075, 0.75 and 20.0 mg / mL; the concentration of iopromide is 0.025, 0.075, 0.75 and 20.0 mg / mL; the concentration of iodixanol is 0.05, 0.15, 1.50 and 40.0 mg / mL.

[0034] In some embodiments, the method for preparing a quality control plasma sample solution comprises: taking a certain amount of standard curve working solution of different concentrations, diluting with blank plasma, and preparing a quality control plasma sample solution. In some embodiments, in the quality control plasma sample solution, the concentration of iohexol is 5.00, 15.0, 150 and 4000 μg / mL; the concentration of iopromide is 5.00, 15.0, 150 and 4000 μg / mL; the concentration of iodixanol is 10.0, 30.0, 300 and 8000 μg / mL.

[0035] In some embodiments, the preparation method of the internal standard stock solution comprises: diluting the internal standard with water. In some embodiments, the concentration of the internal standard stock solution is 1.00 mg / mL.

[0036] In some embodiments, the preparation method of the internal standard working solution comprises: taking an appropriate amount of the internal standard stock solution and diluting it with methanol. In some embodiments, the concentration of the internal standard working solution is 30.0 μg / mL.

[0037] Advantageous Effects of the Invention

[0038] (1) The present invention establishes a fast, stable and sensitive UPLC-MS / MS method for quantitatively analyzing iohexol, iopromide and iodixanol in plasma for the first time. The chemical structures of iohexol, iopromide and iodixanol all contain iodine atoms. The present invention adopts the positive ionization mode of the electrospray ionization (ESI) source, which has better ionization performance and stable response. In addition, the present invention optimizes the source / gas and compound parameters (including capillary voltage, collision voltage, etc.) to obtain the most suitable ionization conditions.

[0039] (2) Since there is a benzene ring in the chemical structure of iohexol, iopromide and iodixanol, reverse phase chromatography is preferred. The inventor has studied various chromatographic conditions (comprising chromatographic column, mobile phase composition, elution procedure, etc.), and obtained an embodiment of the present invention. By the method of the present invention, good chromatographic peak shape and higher sensitivity can be obtained. At the same time, the analysis time is also greatly shortened, thereby improving the analysis efficiency.

[0040] (3) The inventors have demonstrated through methodological experiments that, under the conditions described in the present invention, the matrix effect of plasma samples treated by protein precipitation method is negligible, clear chromatographic peaks can be obtained, and the method of the present invention has good reproducibility. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1A , 1B A and 1C show representative mass chromatograms of iohexol, iopromide, and iodixanol in blank plasma samples, respectively.

[0042] Figure 2A , 2B 2C and 2D show representative mass chromatograms of iohexol, iopromide, and iodixanol in the lower limit of quantitation sample, respectively.

[0043] Figure 3A , 3B 3C and 3D show typical standard curve graphs for iohexol, iopromide, and iodixanol, respectively.

[0044] Figure 4 Representative curves of the pharmacokinetics of iohexol, iopromide, and iodixanol in subjects are shown. DETAILED DESCRIPTION

[0045] The technical solution of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.

[0046] The following describes specific embodiments of the technical solutions of the present invention, but those skilled in the art will appreciate that the following specific embodiments are only some examples of various solutions for implementing the present invention, and they should not be construed as limiting the scope of the present invention in any way.

[0047] In order to provide a more concise description, the quantitative data herein do not use the term "about". It should be understood that, whether the term "about" is used explicitly or not, each numerical value given here includes not only the actual given value (given value), but also means to include an approximate value to such given value reasonably inferred by a person of ordinary skill in the art, including equivalent values ​​and approximate values ​​of such given value due to experimental and / or measurement conditions. The approximate value is preferably ±20%, ±15%, ±10%, ±8%, ±6%, ±5%, ±4%, ±3%, 2%, ±1% based on the given value.

[0048] In some embodiments, the numerical ranges and numerical parameters describing the broad scope of some embodiments of the present invention are approximate and should be interpreted in light of the number of reported significant digits and by applying ordinary rounding techniques. Although the numerical values ​​set forth in the specific examples are reported as accurately as possible, the numerical values ​​presented in some embodiments of the present invention may contain certain errors, which are errors necessarily caused by the standard deviation in the testing measurements.

[0049] 1. Chemicals and Reagents

[0050] The standard samples of the compounds iohexol (purity 80.18%), iopromide (purity 100%), and iodixanol (purity 99.02%) were provided by Target Molecule Corp.; the standard sample of the compound D-5 iohexol internal standard (purity: 95.00%) was provided by Shanghaiyuanye Bio-Technology Co.

[0051] HPLC grade acetonitrile was purchased from Honeywell Burdick & Jackson (ML, USA); analytical grade formic acid was purchased from Sigma-Aldrich chemicals (MO, USA); blank plasma was provided by Peking Union Medical College Hospital (Beijing, China). Deionized water was purified by Milli-Q system (Millipore, Bedford, MA, USA).

[0052] 2. Chromatographic and mass spectrometry conditions

[0053] 2.1 Chromatographic conditions

[0054] Chromatographic columns

[0055] Different types of chromatographic columns were selected, and the method parameters such as mobile phase type, elution conditions, flow rate, etc. were adjusted comprehensively according to the detection effect, and the detection of the test solution in different types of chromatographic columns was investigated. The specific information of the chromatographic columns studied is shown in Table 1 below.

[0056] Table 1: Column information

[0057] model Specification ACQUITY UPLC HSS T3 Columns 2.1×50mm, 1.8μm ACQUITY UPLC CSH C18 Column 2.1×50mm, 1.8μm ACQUITY UPLC BEH C18 Column 2.1×50mm, 1.7μm

[0058] The results show that the above three chromatographic columns are all suitable for the method of the present invention, and can obtain good chromatographic peak shape, high response and good separation. In a specific embodiment, ACQUITY UPLC BEH C18 chromatographic column is preferably used.

[0059] Mobile phase composition

[0060] In ultra-high performance liquid chromatography, elution is performed using a mixed mobile phase consisting of a mobile phase A and a mobile phase B. Specifically, acetonitrile is selected as the mobile phase A (organic phase), and an aqueous solution containing 0.1 volume % to 0.5 volume %, preferably 0.2 volume % of formic acid is selected as the mobile phase B (aqueous phase). The inventors of the present application have found that when an aqueous formic acid solution within the above concentration range is used, ultra-high performance liquid chromatography exhibits an improved separation effect.

[0061] Flow rate

[0062] The effect of the flow rate of the mobile phase on the detection effect was investigated. The flow rates of 0.2 mL / min, 0.3 mL / min, 0.4 mL / min, 0.5 mL / min and 0.6 mL / min were selected for detection, and other experimental conditions were the same.

[0063] The results show that when the flow velocity is greater than 0.5mL / min, the elution time is early, and it is impossible to fully separate from the impurities that flow out together, affecting the sensitivity of detection. When the flow velocity is less than 0.3mL / min, the elution time is late, and the chromatographic column retention effect is stronger. In particular, when the flow velocity is 0.4mL / min, the elution time of iohexol, iopromide, and iodixanol is 0.42, 0.57, and 0.61 minutes, respectively, and the retention effect is good. Therefore, the flow velocity of 0.4mL / min is preferably selected.

[0064] The specific chromatographic conditions used are outlined below.

[0065] Column: Acquity BEH C 18 Column (2.1×50 mm, 1.7 μm)

[0066] Mobile phase A: acetonitrile

[0067] Mobile phase B: aqueous solution containing 0.2 vol% formic acid

[0068] Elution program: isocratic elution; 0.00-1.50 min, 80 vol% mobile phase B + 20 vol% mobile phase A

[0069] Column temperature: 35.0℃

[0070] Autosampler temperature: 4.0°C

[0071] Injection volume: 2.00 μL

[0072] Flow rate: 0.4mL / min

[0073] To reduce carryover, the autosampler syringe and injection valve were cleaned with acetonitrile-water solution containing 1% formic acid (90:10; v / v) (strong wash) and acetonitrile-water solution containing 1% formic acid (10:90; v / v) (weak wash).

[0074] 2.2 Mass spectrometry conditions

[0075] Mass spectrometry analysis was performed using a Xevo TQ-S triple quadrupole mass spectrometer (Waters, MA, USA) in the positive ion mode of the electrospray ionization (ESI) source and multiple reaction monitoring (MRM) scanning detection.

[0076] Adjust the desolvation gas flow, ion source temperature, capillary voltage, collision gas flow, cone voltage, collision voltage and other parameters, and finally determine the following conditions:

[0077] Quantitative ion pair of iohexol: m / z 821.9→m / z 803.7;

[0078] Quantitative ion pair of iopromide: m / z 791.9→m / z 572.7;

[0079] Quantitative ion pair of iodixanol: m / z 1551.2→m / z 1533.0;

[0080] Quantitative ion pair of D5-iohexol: m / z 826.5→m / z 808.5;

[0081] The desolvation gas flow rate was 1000 L / h; the ion source temperature was 500 °C; the capillary voltage was 3.0 kV; the collision gas flow rate was 0.10 mL / min; and the cone voltage was 50 V.

[0082] The collision voltages of iohexol, iopromide, iodixanol and D5-iohexol were 30 V, 32 V, 35 V and 20 V, respectively.

[0083] The specific tandem mass spectrometry parameters used are summarized in Table 2 below.

[0084] Table 2: Tandem mass spectrometry parameters

[0085]

[0086] 3. Preparation of Stock Solutions, Calibration Standards, and Quality Control Samples

[0087] (1) Stock solutions of iodinated contrast agents (25.0 mg / mL, 25.0 mg / mL, and 50.0 mg / mL): Accurately weigh the standards of iohexol, iopromide, and iodixanol, transfer them to a volumetric flask, and dissolve and dilute to volume with pure water. This stock solution is used to prepare the standard curve working solution and quality control (QCs) working solution.

[0088] (2) Standard curve working solution: Take appropriate amounts of the stock solutions of the compounds iohexol, iopromide and iodixanol, respectively, and further dilute them with pure water to prepare standard curve working solutions of different concentrations. The concentrations of iohexol are 0.025, 0.125, 0.625, 1.25, 2.50, 6.25, 12.5 and 25.0 mg / mL; the concentrations of iopromide are 0.025, 0.125, 0.625, 1.25, 2.50, 6.25, 12.5 and 25.0 mg / mL; the concentrations of iodixanol are 0.05, 0.25, 1.25, 2.50, 5.00, 12.5, 25.0 and 50.0 mg / mL.

[0089] (3) Standard curve plasma sample solution: Take a certain amount of standard curve working solution of different concentrations, dilute with blank plasma, and finally obtain a series of standard curve plasma sample solutions. In the standard curve plasma sample solution, the concentration of iohexol is 5.00, 25.0, 125, 250, 500, 1250, 2500 and 5000 μg / mL; the concentration of iopromide is 5.00, 25.0, 125, 250, 500, 1250, 2500 and 5000 μg / mL; the concentration of iodixanol is 10.0, 50.0, 250, 500, 1000, 2500, 5000 and 10000 μg / mL. They are respectively denoted as S1, S2, S3, S4, S5, S6, S7 and S8. Example: S1 contains 5.00 μg / mL of iohexol and 5.00 μg / mL of iopromide, and 10.0 μg / mL of iodixanol. S1 is the lower limit of quantification (LLOQ), and S8 is the upper limit of quantification (ULOQ).

[0090] (4) Quality control (QCs) working solution: Take appropriate amounts of the stock solutions of the compounds iohexol, iopromide and iodixanol, respectively, and further dilute them with pure water to prepare quality control (QCs) working solutions of different concentrations. In the quality control working solutions, the concentrations of iohexol are 0.025, 0.075, 0.75 and 20.0 mg / mL; the concentrations of iopromide are 0.025, 0.075, 0.75 and 20.0 mg / mL; and the concentrations of iodixanol are 0.05, 0.15, 1.50 and 40.0 mg / mL.

[0091] (5) Quality control plasma sample solution: Take a certain amount of standard curve working solution of different concentrations, dilute it with blank plasma, and prepare quality control plasma sample solution. In the quality control plasma sample solution, the concentrations of iohexol and iopromide are 5.00, 15.0, 150 and 4000 μg / mL; the concentration of iodixanol is 10.0, 30.0, 300 and 8000 μg / mL, which are recorded as the lower limit of quantification (LLOQ), low concentration quality control (LQC), medium concentration quality control (MQC) and high concentration quality control (HQC), respectively. Example: The amount of iohexol, iopromide and iodixanol contained in LLOQ is 5.00, 5.00 and 10.00 μg / mL, respectively).

[0092] (6) Internal standard stock solution (1.00 mg / mL): The internal standard specification of D5-iohexol is 1 mg / bottle. Directly add 1 mL of pure water into the standard stock bottle (1 mg) to prepare the internal standard stock solution.

[0093] (7) Internal standard working solution: Take an appropriate amount of the internal standard stock solution and dilute it with methanol to obtain an internal standard working solution with a concentration of 30 μg / mL.

[0094] The above solutions and plasma samples were stored frozen at -30°C and -80°C.

[0095] 4. Plasma sample pretreatment method

[0096] The specific method for processing the plasma sample in the present invention is as follows:

[0097] Take 10.0μL of plasma sample and add it to an EP tube. Add 200μL of internal standard working solution (30.0μg / mL, solvent is methanol) to precipitate protein, shake for 1 minute, and then centrifuge at 13300rpm for 10 minutes. Take 50μL of supernatant and place it in a new EP tube, add 1ml of pure water; after mixing, further dilute with water, take 100μL of the mixture and add it to 1mL of pure water, mix well and inject. The injection volume is 2.00μL.

[0098] Example 1: Selectivity

[0099] 1. Methods

[0100] Six blank matrices of human plasma samples from different individuals were taken, and one double blank (DB) sample and one lower limit of quantitation (LLOQ) sample were prepared from each blank matrix. The detection results of DB samples and LLOQ samples were compared to evaluate the selectivity of the method.

[0101] Acceptance criteria: If there is a certain interference in the DB sample at the corresponding retention time of the analyte, this interference shall not be greater than 20% of the average peak area of ​​the analyte in the LLOQ sample; when the internal standard method is used for quantitative determination, the chromatographic peak area at the corresponding retention time of the internal standard shall not be greater than 5% of the average peak area of ​​the internal standard in the standard curve and quality control samples.

[0102] 2. Results

[0103] According to the UPLC-MS / MS conditions selected in the present invention, the mass chromatograms of each DB sample and LLOQ sample were measured respectively.

[0104] Figure 1A , 1B A and 1C show representative mass chromatograms of iohexol, iopromide, and iodixanol in blank plasma samples, respectively. Figure 2A , 2B 2C and 2D show representative mass chromatograms of iohexol, iopromide, and iodixanol in the lower limit of quantitation sample, respectively.

[0105] The peak areas of representative DB plasma samples and LLOQ plasma samples of iohexol, iopromide, and iodixanol at the retention time (RT) of each compound are summarized in Table 3 below.

[0106] Table 3: Selectivity

[0107]

[0108] Depend on Figure 1A , 1B and 1C and Figure 2A , 2B As can be seen from Tables 2C and 3, under the experimental conditions of the present invention, the plasma matrix has no interference in the separation and determination of the analyte and the internal standard. Therefore, the method of the present invention meets the above acceptance criteria.

[0109] Example 2: Linear Relationship

[0110] 1. Methods

[0111] Two sets of standard curve samples containing 8 concentration points were processed and measured. The measurements of these two sets of standard curve samples were placed at the beginning and end of each analysis batch. The peak area ratio of iohexol, iopromide and iodixanol to the internal standard was taken as Y, and the concentration was taken as X, and the fitting was performed respectively. The weight coefficient was 1 / X 2 , the curve regression equation of the standard curve is Y = aX + b. Each analysis batch includes 1 double blank sample (DB) and 1 blank sample (BK) to ensure that the blank matrix and the added reagents have no interference with the detection of the compound.

[0112] Acceptance criteria: good linearity, R ≥ 0.990 or R2 ≥ 0.980; the concentration of the calibration standard should be within 85%-115% of the labeled value, and the lower limit of quantification should be within 80%-120%. At least 75% of the calibration standards (minimum 6 valid concentrations) should meet the above requirements; at least 50% of the calibration standards at the same concentration point should meet the above requirements.

[0113] 2. Results

[0114] The following Tables 4-1, 4-2 and 4-3 respectively give the back-calculated concentration results of the standard curve plasma samples of iohexol, iopromide and iodixanol.

[0115] Table 4-1: Back-calculated concentrations of the standard curve - Iohexol

[0116]

[0117] Table 4-2: Back-calculated concentrations of the standard curve - Iopromide

[0118]

[0119] Table 4-3: Back-calculated concentrations of the standard curve - Iodixanol

[0120]

[0121] Note: %CV: precision or coefficient of variation; %Bias: accuracy deviation

[0122] Figure 3A , 3B 3C and 3D show typical standard curve graphs for iohexol, iopromide, and iodixanol, respectively.

[0123] The linearity of the standard curves for iohexol, iopromide, and iodixanol is summarized in Table 5.

[0124] Table 5: Linear relationship

[0125]

[0126] According to the test results, for all batches of samples, iohexol has a good linear relationship with the ratio of the peak area in the concentration range of 5.00-5000 μg / mL, iopromide has a good linear relationship with the ratio of the peak area in the concentration range of 5.00-5000 μg / mL, and iodixanol has a good linear relationship with the ratio of the peak area in the concentration range of 10.0-10000 μg / mL. For all batches of samples, the R2 values ​​of the standard curves of the compounds iohexol, iopromide and iodixanol are all between 0.990 and 1.000.

[0127] Example 3: Precision and Accuracy

[0128] 1. Methods

[0129] Each batch of precision and accuracy validation should use independently prepared and freshly prepared standard curves and QC samples; precision and accuracy should not fail two consecutive analysis batches, and at least pass two consecutive analysis batches, and be performed at least on two days; six quality control samples are taken at the lower limit of quantitation (LLOQ), low concentration quality control (LQC), medium concentration quality control (MQC), and high concentration quality control (HQC) concentration levels to evaluate intra-batch and inter-batch precision and accuracy. Intra-batch precision and accuracy are evaluated in a single batch, and inter-batch precision and accuracy are evaluated between three consecutive batches.

[0130] Intra-batch / inter-batch accuracy acceptance criteria: The mean of the measured values ​​of the quality control samples at the three concentration levels of low, medium and high should be within the range of 85%-115% of their labeled values, and the six quality control samples at each concentration level should meet the requirement that at least 67% of the sample measured values ​​are within the range of 85%-115% of their labeled values. For LLOQ samples, the mean of the measured values ​​should be within the range of 80%-120% of their labeled values, and at least 67% of the sample measured values ​​should be within the range of 80%-120% of their labeled values. Intra-batch / inter-batch precision acceptance criteria: The coefficient of variation within and between batches shall generally not exceed 15%, and the coefficient of variation of the lower limit of quantification shall not exceed 20%.

[0131] 2. Results

[0132] The test results show that the inter-batch / intra-batch precision of the quality control samples of each compound at each concentration level is less than or equal to 9.12%. Therefore, the accuracy and precision values ​​of the method of the present invention meet the specified acceptance criteria, which shows that the method of the present invention is reliable and reproducible for the determination of iohexol, iopromide and iodixanol.

[0133] Example 4: Extraction recovery

[0134] 1. Methods

[0135] Different amounts of standard substances were added to a certain amount of blank plasma matrix to prepare validation samples of low, medium and high concentrations, and then extracted. The blank plasma matrix was extracted, and the solution was used as a solvent to prepare a reference solution of the same concentration. The response values ​​of the two were compared to calculate the extraction recovery of the method.

[0136] Internal standard extraction recovery rate: Add a certain amount of internal standard reference substance (the amount added is equal to the amount used in the sample preparation process) to the blank plasma matrix to prepare the verification sample, and then extract it. Compare it with the response value of the internal standard reference substance solution of the same concentration prepared with the blank plasma matrix extraction solution as the solvent, and calculate the internal standard extraction recovery rate.

[0137] Acceptance criteria: The absolute value of the extraction recovery rate of low, medium and high concentration quality control samples should not exceed 115%, the CV% of the peak area at each concentration level should be less than 15%, and the CV% of the extraction recovery rate at the three concentration levels should not exceed 20%.

[0138] 2. Results

[0139] The following Tables 6-1 and 6-2 summarize the extraction recoveries of the analytes and internal standards in plasma, respectively.

[0140] Table 6-1: Extraction recovery of analytes

[0141]

[0142] Note:

[0143] LQC: Low concentration quality control sample

[0144] MQC: Medium concentration quality control sample

[0145] HQC: High concentration quality control sample

[0146] %CV: Precision or coefficient of variation

[0147] Table 6-2: Internal standard extraction recovery

[0148]

[0149] It can be seen from the above results that the extraction recovery rate of the method of the present invention meets the prescribed acceptance criteria.

[0150] Example 5: Matrix Effect

[0151] 1. Methods

[0152] Six different sources of blank plasma were used to evaluate the effects of different matrix sources on the assay at LQC, MQC, and HQC concentration levels. The matrix factor of each analyte and internal standard was calculated by calculating the ratio of the peak area in the presence of matrix (measured by adding analytes and internal standards after extraction of blank matrix) to the corresponding peak area without matrix (pure solutions of analytes and internal standards); the matrix factor normalized by the internal standard (Absolute MF%) was further calculated by dividing the matrix factor of the analyte (Analyte MF%) by the matrix factor of the internal standard (IS MF%). If the inter-individual variation of the matrix effect of the compound and the internal standard is less than 15%, it meets the requirements.

[0153] 2. Results

[0154] The results for the matrix effects of iohexol, iopromide, and iodixanol are summarized in Table 7 below.

[0155] Table 7: Matrix effects of iohexol, iopromide and iodixanol

[0156]

[0157] From the above results, it can be seen that the matrix effect of the method of the present invention meets the above requirements.

[0158] Example 6: Stability

[0159] 1. Methods

[0160] The stability of the analytes was evaluated by analyzing LQC samples (n=6) and HQC samples (n=6) under various storage, processing and analytical conditions. The stability of the stock solutions was evaluated by comparing the peak areas of the freshly prepared solutions with the storage solutions (8 hours at room temperature, -30°C and 67 days at -80°C). The stability of the working solutions was evaluated by comparing the peak areas of the freshly prepared solutions with the working solutions (8 hours at room temperature, -30°C and 67 days at -80°C).

[0161] The stability of the analytes in plasma was tested under different conditions. To evaluate short-term and long-term stability, samples were stored at room temperature for 8 hours, -30°C, and -80°C for 66 days. The extracted samples were placed in an autosampler (4°C) for 48 hours and subsequently analyzed using a freshly prepared standard curve to evaluate the stability of the autosampler. In addition, the prepared samples were stored in a refrigerator (4°C) for 50 hours and then re-injected to evaluate the stability of repeated injections. For freeze-thaw stability, the samples were frozen at -80°C for more than 12 hours, with an appropriate time of 4 hours between freeze-thaw cycles. A total of 3 freeze-thaw cycles were performed.

[0162] 2. Results

[0163] This study investigated the stability of iohexol, iopromide, and iodixanol in solution and plasma under different storage and handling conditions during routine analysis.

[0164] 1) Stability of mother solutions: The test results show that the mother solutions of iohexol, iopromide, iodixanol and internal standard D5-iohexol stored at -30°C and -80°C for 67 days have good stability; the mother solutions of iohexol, iopromide, iodixanol and internal standard D5-iohexol stored at room temperature for 8 hours have good stability.

[0165] 2) Stability of working solutions: The test results show that the working solutions of iohexol, iopromide, iodixanol and internal standard D5-iohexol stored at -30°C and -80°C for 67 days have good stability; the working solutions of iohexol, iopromide, iodixanol and internal standard D5-iohexol stored at room temperature for 8 hours have good stability.

[0166] 3) Stability during biological sample pretreatment: Short-term stability: iohexol, iopromide and iodixanol in plasma remained stable after storage at room temperature for 8 hours; Long-term frozen storage stability: iohexol, iopromide and iodixanol in plasma remained stable after storage at -30°C and -80°C for 66 days.

[0167] 4) Freeze-thaw stability: Iohexol, iopromide and iodixanol in plasma can withstand at least three repeated freeze-thaw cycles (-80°C to room temperature).

[0168] 5) Sample stability after preparation: Iohexol, iopromide and iodixanol in plasma samples after sample pretreatment were stored in an autosampler (4°C) for 48 hours and quantified using a freshly prepared standard curve with accuracy and precision meeting the requirements.

[0169] 6) Repeated injection reproducibility: After storage at 4°C for 50 hours, the accuracy and precision of iohexol, iopromide and iodixanol in plasma samples after sample pretreatment were repeated and injected, and met the requirements.

[0170] Example 7: Residual Effect

[0171] 1. Methods

[0172] At least one DB sample should be injected and measured after the first upper limit of the standard curve in each analytical batch to evaluate whether there is any carryover of the high-concentration sample in the blank plasma sample.

[0173] Acceptance criteria: The peak area of ​​the analyte after the quantitative upper limit in the DB sample should not exceed 20% of the average peak area of ​​the analyte after the quantitative lower limit, and the peak area of ​​the internal standard in the DB sample should not exceed 5% of the average peak area of ​​the internal standard after the quantitative lower limit.

[0174] 2. Results

[0175] In the blank plasma sample after the upper limit of quantification, the residues present at the retention time of the analytes iohexol, iopromide and iodixanol were less than 20.0% of the mean peak area of ​​the lower limit of quantification of the batch. Therefore, the method of the present invention meets the above acceptance criteria.

[0176] Example 8: Pharmacokinetic Application

[0177] The method of the present invention is used to detect the pharmacokinetics of iohexol, iopromide and iodixanol in the plasma of Chinese patients in a study initiated by a researcher. In order to explore the differences in the elimination characteristics of three iodinated contrast agents of different concentrations in the human body from the perspective of in vivo pharmacokinetics, help clinicians understand the situation of the patient's glomerular filtration rate, and evaluate their renal function, this researcher-initiated study was carried out. In the study, a total of 5 subjects were selected for this study, and the research drugs were iohexol, iopromide and iodixanol injection; blood samples of the subjects at different time points after intravenous injection were collected. The plasma pretreatment method and ultra-high performance liquid chromatography-tandem mass spectrometry quantitative method provided by the present invention are used to analyze the pharmacokinetic characteristics of iohexol, iopromide and iodixanol in human plasma after different administration methods. The glomerular filtration rate of the three drugs is extrapolated by their clearance rate, which helps clinicians evaluate the patient's renal function and formulate reasonable clinical treatment strategies. Figure 4 Representative curves of the in vivo pharmacokinetics of iohexol, iodixanol, and iopromide following intravenous injection are shown.

[0178] As can be known from the above description, method of the present invention is applicable to the quantitative analysis of iohexol, iopromide and iodixanol simultaneously, and has the advantages such as high sensitivity, good stability, strong specificity and strong data reproducibility compared with the prior art, and has higher practicality and reliability. In addition, method analysis time of the present invention is short, and iohexol, iopromide and iodixanol in blood plasma can be accurately and efficiently quantitatively analyzed. This is of great significance for the clinical pharmacokinetic study of iohexol, iopromide and iodixanol.

[0179] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed in this disclosure should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the attached claims.

Claims

1. A method for quantitatively analyzing iodinated contrast agents in plasma by ultra-high performance liquid chromatography-tandem mass spectrometry, the method comprising the following steps: 1) preparing a plasma sample solution containing an iodinated contrast agent; 2) injecting the plasma sample solution into an ultra-high performance liquid chromatography-tandem mass spectrometry device to obtain a mass chromatogram; and 3) performing quantitative analysis on the iodine contrast agent using an internal standard method according to the mass chromatogram, wherein the iodine contrast agent comprises at least one selected from iohexol, iopromide and iodixanol, and In the ultra-high performance liquid chromatography, a mixed mobile phase consisting of a mobile phase A and a mobile phase B is used for elution, wherein the mobile phase A is acetonitrile, and the mobile phase B is an aqueous solution containing 0.1 volume % to 0.5 volume % of formic acid.

2. The method according to claim 1, wherein isocratic elution is performed in the ultra-high performance liquid chromatography, and the volume ratio of mobile phase A to mobile phase B in the mixed mobile phase is in the range of 10:90 to 30:

70.

3. The method according to claim 2, wherein the volume ratio of the mobile phase A to the mobile phase B is 20:

80.

4. The method according to claim 1, wherein D5-iohexol is used as an internal standard.

5. The method according to claim 1, wherein the chromatographic column in the ultra-high performance liquid chromatography is a reverse phase chromatography column.

6. The method according to claim 1, wherein the preparing the plasma sample solution containing the iodinated contrast agent comprises: The internal standard working solution was added to the plasma sample of the subject, the resulting mixture was shaken and then centrifuged, and water was added to the supernatant and mixed.

7. The method according to claim 6, wherein the internal standard working solution is prepared by dissolving the internal standard substance D5-iohexol in water to obtain an internal standard stock solution, and then diluting the internal standard stock solution with methanol.

8. The method of claim 1, wherein the mass spectrometry conditions include: A triple quadrupole mass spectrometer was used with an electrospray ionization source in positive ion mode and multiple reaction monitoring detection.

9. The method according to claim 8, wherein in the multiple reaction monitoring scanning detection, the quantitative ion pair of iohexol is m / z 821.9→m / z 803.7, the quantitative ion pair of iopromide is m / z 791.9→m / z 572.7, the quantitative ion pair of iodixanol is m / z 1551.2→m / z 1533.0, and the quantitative ion pair of D5-iohexol is m / z 826.5→m / z 808.

5.

10. The method according to claim 8, wherein in the tandem mass spectrometry, the collision voltage of iohexol is 30V, the collision voltage of iopromide is 32V, the collision voltage of iodixanol is 35V, and the collision voltage of D5-iohexol is 20V.